<DOC>
	<DOCNO>NCT00266708</DOCNO>
	<brief_summary>Patients kidney failure underlie bone disease time transplant . Fractures various bone high 22 % . Medication require transplant play role bone loss . Bisphosphonates use general population treat bone loss osteoporosis steroid-induced bone loss . While previous study , use various bisphosphonates , show preservation bone mineral density renal transplant recipient , demonstrate pamidronate , second generation bisphosphonate , associate low bone turnover still preserve bone mineral density . Improved bone mineral density associate decreased fracture risk general population , low bone turnover may associate increased fracture dialysis patient . The purpose study determine whether risedronate , third generation bisphosphonate , effective preserve bone density give prophylactically follow renal transplantation whether associate low bone turnover one year follow renal transplantation .</brief_summary>
	<brief_title>Randomized Trial Risedronate Prevent Bone Loss Renal Transplant Recipients .</brief_title>
	<detailed_description>Participants receive live donor kidney transplant undergo bone biopsy time kidney transplant one year protocol . Once adequate kidney function establish , group take mouth weekly capsule ( control group placebo ; treatment group risedronate 35 mg ) . Both group undergo baseline , 6 month 12 month DEXA bone mineral density scan . Both group undergo bone hormonal study regular interval .</detailed_description>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Adults end stage renal disease undergo live donor kidney transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>renal transplant</keyword>
	<keyword>post-transplant osteoporosis</keyword>
</DOC>